Data support the use of high-molecular-weight matrix metalloproteinases (MMPs), such as the LCN2-MMP-9 complex, as independent predictors of metastatic phenotypes in several cancers, including prostate and bladder cancers [78]. Here, LCN2 is linked to cancer.